Akebia Ther (AKBA)

Currency in USD
3.320
-0.030(-0.90%)
Closed·
3.340+0.020(+0.60%)
·
AKBA Scorecard
Full Analysis
Stock has taken a big hit over the last week
AKBA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.2903.400
52 wk Range
1.2404.079
Key Statistics
Prev. Close
3.35
Open
3.36
Day's Range
3.29-3.4
52 wk Range
1.24-4.079
Volume
3.06M
Average Volume (3m)
4.78M
1-Year Change
169.92%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AKBA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.500
Upside
+125.90%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Akebia Ther News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Akebia Ther Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Employees
181

Akebia Ther Earnings Call Summary for Q2/2025

  • Q2 2025 revenue beat expectations at $62.5M, up 43% YoY, but EPS missed at $0 vs -$0.02 forecast
  • Vasceo sales grew 55% QoQ to $13.3M; company aims to reach 275,000+ patients by Q4 2025
  • Stock dropped 18.49% to $3.2 pre-market despite revenue beat, reflecting EPS miss concerns
  • Strong cash position of $137.3M; VALOR trial for non-dialysis CKD patients to start by end of 2025
  • FY2025 revenue projected at $201.81M; analyst price targets range $6-$10 with strong buy consensus
Last Updated: 07/08/2025, 15:54
Read Full Transcript

Compare AKBA to Peers and Sector

Metrics to compare
AKBA
Peers
Sector
Relationship
P/E Ratio
−24.1x−1.3x−0.5x
PEG Ratio
−1.100.010.00
Price/Book
30.1x1.6x2.6x
Price / LTM Sales
4.3x5.2x3.3x
Upside (Analyst Target)
111.2%46.8%41.6%
Fair Value Upside
Unlock25.1%5.9%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.500
(+125.90% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-- / -0.02
Revenue / Forecast
62.47M / 47.64M
EPS Revisions
Last 90 days

AKBA Income Statement

People Also Watch

75.91
WDC
+1.70%
4.130
ATAI
+4.29%
192.00
ALAB
+7.01%
125.38
CRDO
+5.74%
49.760
ASTS
+8.36%

FAQ

What Stock Exchange Does Akebia Ther Trade On?

Akebia Ther is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Akebia Ther?

The stock symbol for Akebia Ther is "AKBA."

What Is the Akebia Ther Market Cap?

As of today, Akebia Ther market cap is 880.28M.

What Is Akebia Ther's Earnings Per Share (TTM)?

The Akebia Ther EPS (TTM) is -0.16.

When Is the Next Akebia Ther Earnings Date?

Akebia Ther will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is AKBA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Akebia Ther Stock Split?

Akebia Ther has split 0 times.

How Many Employees Does Akebia Ther Have?

Akebia Ther has 181 employees.

What is the current trading status of Akebia Ther (AKBA)?

As of 13 Aug 2025, Akebia Ther (AKBA) is trading at a price of 3.32, with a previous close of 3.35. The stock has fluctuated within a day range of 3.29 to 3.40, while its 52-week range spans from 1.24 to 4.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.